Life Sciences Transactions
Life sciences innovators and investors know that well-executed transactions are critical to their life-enhancing products and technologies. Our internationally recognized Life Sciences Transactions team provides clients across all sizes and subsectors with the breadth and depth needed to get the full range of their increasingly complex deals done efficiently and effectively. From M&A and financings to licensing, collaborations, commercial arrangements, and digital health and technology deals, we integrate our extensive US, EU and China transactional, intellectual property, technology, regulatory, antitrust, and litigation experience to help a "who’s who" of life sciences companies and healthcare providers secure mission-critical deals that enhance their ability to advance the standard for care in their ever-evolving, highly regulated industry.
Broad Client Base: For decades, we have advised major pharmaceutical companies, specialty pharmaceutical companies, biotechs, medical device, diagnostic, and health technology companies, nonprofits and universities, healthcare providers, and investors, among others.
Cutting-Edge Transactions: We assist our clients with complex transactions involving the most cutting-edge science in the industry and novel deal structures designed to provide beneficial outcomes to all parties in an ever-changing business and scientific landscape.
Deals Done Right: Our Life Sciences Transactions team fully integrates experienced transactional attorneys; deep IP, technology, regulatory, and reimbursement expertise; and renowned antitrust/merger clearance capabilities in an efficient and cost-effective manner.
AstraZeneca in agreements for the funding and global distribution of the University of Oxford's potential COVID-19 vaccine, as well as in the establishment of its global manufacturing and supply chain for the vaccine, including agreements with the Coalition for Epidemic Preparedness Innovations (CEPI), Gavi the Vaccine Alliance (Gavi), the Serum Institute of India (SII), the Biomedical Advanced Research and Development Authority (BARDA) in the US, and the governments of Germany, France, Italy, and the Netherlands.
Sanofi in a long-term research collaboration with Kymera Therapeutics to discover, develop and commercialize first-in-class protein degrader therapies for patients with immune-inflammatory diseases.
Alcon in its acquisition of PowerVision, a medical device company focused on creating fluid-based intraocular lens implants for cataract patients.
Carestream Health in the sale of its healthcare information systems (HCIS) business to Royal Philips, a global leader in health technology.
Novartis in the sale to Mylan of its global cystic fibrosis products, including the TOBI® Podhaler and TOBI® solution.
Pfizer in the acquisition of Therachon Holding AG, a privately held clinical-stage biotechnology company focused on rare diseases.
Pfizer in the joint creation of Cerevel Therapeutics (a new biopharmaceutical company focused on developing drug candidates to treat central nervous system disorders) with Bain Capital whereby Pfizer contributed a portfolio of pre-commercial neuroscience assets to Cerevel in return for a 25% equity position in the company, while Bain Capital committed initial funding with the ability to provide additional capital.